Lung Ultrasound Findings Associated With COVID-19 ARDS, ICU Admission, and All-Cause Mortality

• DOI: 10.4187/respcare.09108
• Publication Date: 2021-11-23T21:07:11Z
• Authors: Caroline Espersen; Elke Platz; Kristoffer Grundt...; Mats Christian Hø...; Jannie Nørgaard Lind; Niklas Dyrby Joha...; Morten Sengeløv; Alia Saed Alhakak; Anne Bjerg Nielsen; Henning Bundgaard; Christian Hassager; Reza Jabbari; Jørn Carlsen; Ole Kirk; Matias Greve Lind...; Ole Peter Kristia...; Olav Wendelboe Ni...; Klaus Nielsen Jes...; Charlotte Suppli ...; Pradeesh Sivapalan; Gunnar Gislason; Kasper Iversen; Jens Ulrik Stæhr ...; Morten Schou; Søren Helbo Skaarup; Tor Biering-Sørensen
• Keywords: Procalcitonin

As lung ultrasound (LUS) has emerged as a diagnostic tool in patients with COVID-19, we sought to investigate the association between LUS findings and composite in-hospital outcome of ARDS incidence, ICU admission, all-cause mortality.In this prospective, multi-center, observational study, adults laboratory-confirmed SARS-CoV-2 infection were enrolled from non-ICU in-patient units. Subjects underwent an evaluating total 8 zones. Images analyzed off-line, blinded clinical variables outcomes. A score was developed integrate findings: ≥ 3 B-lines corresponded 1, confluent 2, subpleural or lobar consolidation 3. The ranged 0-24 per subject.Among 215 subjects, 168 data no current signs admission (mean age 59 y, 56% male) included. One hundred thirty-six (81%) subjects had pathologic 1 zone (≥ B-lines, consolidations). Markers disease severity at baseline higher (n = 31, 18%), including median C-reactive protein (90 mg/L vs 55, P < .001) procalcitonin levels (0.35 μg/L 0.13, .033) supplemental oxygen requirements (median 4 L/min .001). However, did not differ significantly those without, associated outcomes unadjusted adjusted logistic regression analyses.Pathologic on common d after cohort hospitalized COVID-19 among who experienced incident ARDS, mortality compared not. These should be confirmed future investigations. study is registered Clinicaltrials.gov (NCT04377035).